FDA's promotion for cell and tissue products - the TRG Rapid Inquiry Program (TRIP)
![Pharmaceutical Biotechnology for Non-Biotechnologists](files/eca/userImages/training.img/Z-ECA-Pharmaceutical-Biotechnology-Non-Biotechnologists.jpg)
Recommendation
9/10 October 2024
Berlin, Germany
An Overview and Insight in Pharmaceutical Biotechnology
The FDA had already announced its strategy for regenerative medicine, including cell therapies, in November 2017. This included a 36-month period during which those developing such products should evaluate whether their products require pre-market approval. The FDA also announced that it would make use of its discretionary powers with respect to Premarket Approval during this period, if use of the product in question does not raise any reported safety concerns or potentially significant safety concerns.
In a paper published by the FDA on 12 June, "Temporary streamlined program to help manufacturers of human cell, tissue, and cellular and tissue-based products – including stem cell treatments – understand the appropriate regulatory pathways
for their products" , the responsible Acting FDA Commissioner Ned Sharpless notes that half of the timeframe has already passed and that the feedback from developers and manufacturers of human cells, tissues, cellular and tissue-based products was significantly lower than expected. He explains that a temporary programme will therefore be set up to help manufacturers and those who market products to physicians or patients to quickly receive an informal, non-binding FDA assessment of how their products are regulated.
At the same time, he notes that the FDA will continue to respond to the fact that there are many cases where companies make unconfirmed claims about the potential of human cells, tissues and cellular and tissue-based products to prevent, treat or cure serious diseases (see News "FDA keeps an eye on use and marketing of cell and tissue products") .In such cases, the FDA will take action to protect patients. (see News "FDA issues Warning Letter to Manufacturer of Human Cells, Tissue or Cell based Products").
In order to further support the affected manufacturers in the second half of the 36-month period and to submit corresponding inquiries to the FDA, the FDA has launched a temporary programme until 31 December 2019, the Tissue Reference Group (TRG) Rapid Inquiry Program (TRIP), to obtain the above non-binding assessments. The Agency intends to respond to requests containing sufficient details for the evaluation within three days of receipt, if resources permit.
Related GMP News
29.05.2024New FDA Draft Guideline regarding the Use of Human- and Animal-derived Materials
22.05.2024New FDA Draft Guideline regarding Safety Testing of human allogeneic Cells
07.05.2024Final Approval of SoHO Regulation
07.05.2024FDA Warning Letter to a Biotechnology Company in China
07.05.2024Update of Guideline on Epidemiological Data
05.03.2024FDA Warning Letter on misbranded and unapproved Drugs